Bispecific Anti-CCL2 Antibodies for Stronger Binding and Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antibodies targeting CCL2 face high in vivo dissociation constants and clearance rates, hindering effective suppression of CCL2 levels in patients with elevated serum levels or tumor-infiltrating immune cells, which are crucial for treating cancers and inflammatory diseases.
Innovation Solution
Development of bispecific anti-CCL2 antibodies that bind to two different epitopes on human CCL2, utilizing specific CDR sequences and a human IgG isotype Fc domain to enhance antigen binding and cellular uptake, thereby increasing the in vivo clearance rate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional antibodies are used to neutralize CCL2, then the antibody structure is simple and easy to manufacture, but the binding affinity is insufficient due to high dissociation constants, limiting CCL2 suppression at clinically viable doses
Solution Approach 1:
The patent combines two separate antibody binding sites into a single bispecific antibody molecule, where one binding site targets CCL2 and the other targets an immune cell surface marker. This merging allows the antibody to simultaneously bind CCL2 with high affinity and recruit immune cells for enhanced clearance, resolving the contradiction between manufacturing simplicity and binding reliability.
Solution Approach 2:
The bispecific antibody functions as a composite therapeutic agent, integrating two different antigen-binding specificities within one molecular structure. This composite design enables both high-affinity CCL2 binding and immune cell engagement, overcoming the limitations of conventional single-specificity antibodies while maintaining a manageable structural complexity for manufacturing.
2Reliability
If conventional antibodies are used at high doses to overcome high dissociation constants, then binding affinity may be sufficient, but the dosage becomes prohibitively high and reduces clinical viability
Solution Approach 1:
By merging CCL2 binding capability with immune cell recruitment functionality in a single bispecific antibody molecule, the patent achieves potent CCL2 suppression at lower doses. The dual mechanism of direct CCL2 neutralization plus immune-mediated clearance eliminates the need for prohibitively high doses required by conventional antibodies.
Solution Approach 2:
The bispecific antibody acts as an intermediary that bridges CCL2 and immune cells, facilitating targeted clearance of CCL2 by the immune system. This intermediary mechanism amplifies the therapeutic effect at lower doses compared to direct neutralization alone, making clinically viable dosing possible.
3Reliability
If CCL2 levels are neutralized, then the desired anti-tumor and anti-inflammatory effects are achieved, but the high synthesis rate of CCL2 continuously replenishes the antigen, requiring sustained high antibody concentrations
Solution Approach 1:
The bispecific antibody introduces immune cells as active intermediaries that continuously clear CCL2 from the system. This immune-mediated clearance mechanism creates a self-sustaining therapeutic effect that persists longer than passive antibody neutralization alone, addressing the issue of continuous CCL2 replenishment from high synthesis rates.
Solution Approach 2:
The bispecific antibody creates a feedback loop where immune cell recruitment and activation lead to enhanced CCL2 clearance, which in turn reduces the antigen load and allows sustained therapeutic effect. This feedback mechanism helps maintain effective CCL2 suppression over time despite continuous synthesis, extending the duration of action.
Data Source
AI summary
The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.